Results 231 to 240 of about 18,649 (278)
Some of the next articles are maybe not open access.
Idiopathic Inflammatory Myopathies
Indian Journal of Pediatrics, 2023Idiopathic inflammatory myopathies (IIMs) are a diverse group of diseases characterized by proximal muscle weakness and inflammation in skeletal muscle. Phenotypically, the subtypes include dermatomyositis, polymyositis, inclusion body myositis, and amyopathic dermatomyositis. The most common IIM in children is juvenile dermatomyositis (JDM).
Suma Balan, Sumanth Madan
openaire +2 more sources
Best Practice & Research Clinical Rheumatology, 1995
New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies.
C V, Oddis, T A, Medsger
openaire +2 more sources
New information regarding myositis specific autoantibodies, histopathologic analysis of muscle biopsy specimens, and immunogenetic features of the different serologic subsets of disease has greatly increased our understanding of the pathogenesis of the inflammatory myopathies.
C V, Oddis, T A, Medsger
openaire +2 more sources
Current Treatment Options in Neurology, 2011
The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM ...
B Jane, Distad +2 more
openaire +2 more sources
The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM ...
B Jane, Distad +2 more
openaire +2 more sources
Continuum, 2022
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.The classification of idiopathic inflammatory myopathies has improved with the integration of myositis ...
openaire +2 more sources
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2.The classification of idiopathic inflammatory myopathies has improved with the integration of myositis ...
openaire +2 more sources
Current Treatment Options in Neurology, 1999
Patients with polymyositis or dermatomyositis should be treated with prednisone (approximately 1 mg/kg/d) for an initial period of 4 to 6 weeks. Once improvement occurs, the dose should be tapered and converted to an alternate-day regimen, which should be continued for at least 12 months.
, Mastaglia, , Phillips, , Zilko
openaire +2 more sources
Patients with polymyositis or dermatomyositis should be treated with prednisone (approximately 1 mg/kg/d) for an initial period of 4 to 6 weeks. Once improvement occurs, the dose should be tapered and converted to an alternate-day regimen, which should be continued for at least 12 months.
, Mastaglia, , Phillips, , Zilko
openaire +2 more sources
Autoantibodies in Inflammatory Myopathies
The American Journal of the Medical Sciences, 2000Abstract A variety of antibodies directed against cellular constituents, some nuclear and others cytoplasmic, have been reported in patients with inflammatory myopathies; however, it remains uncertain what role, if any, they play in the pathogenesis of these conditions.
Garleep, M.J., Mastaglia, F.L.
openaire +2 more sources
Treatment of inflammatory myopathies
Expert Review of Clinical Immunology, 2018The idiopathic inflammatory myopathies (IIM) dermatomyositis (DM) and polymyositis (PM) are chronic diseases affecting the striated muscles with variable involvement of other organs. Glucocorticoids are considered the cornerstone of treatment, but some patients require adjunctive immunosuppressive agents because of insufficient response to ...
Pipitone, Nicolò€, Salvarani, Carlo
openaire +2 more sources
Veterinary Clinics of North America: Small Animal Practice, 2002
Inflammatory myopathies are the result of infiltration of inflammatory cells into striated muscle, with or without an association with an underlying cause. Two broad classifications are IIMs and secondary inflammatory myopathies associated with other diseases.
openaire +2 more sources
Inflammatory myopathies are the result of infiltration of inflammatory cells into striated muscle, with or without an association with an underlying cause. Two broad classifications are IIMs and secondary inflammatory myopathies associated with other diseases.
openaire +2 more sources
Idiopathic inflammatory myopathies
Best Practice & Research Clinical Rheumatology, 2012Inflammatory myopathies are chronic, immune-mediated diseases characterised by progressive proximal muscle weakness. They encompass a variety of syndromes with protean manifestations. The diagnosis is based on Bohan and Peter's classification criteria, which nowadays seem to be obsolete.
Melinda, Vincze, Katalin, Danko
openaire +2 more sources
Idiopathic Inflammatory Myopathies
Rheumatic Disease Clinics of North America, 1990The idiopathic inflammatory myopathies are a heterogeneous group of uncommon diseases. The incidence rate of IIM is approximately 5 cases per million population, but there appears to be an increase in the rate over the last two decades, particularly in black females.
M E, Cronin, P H, Plotz
openaire +2 more sources